Listed

Enanta Pharmaceuticals Inc

ENTANasdaqCIK 1177648HealthcareFiscal year ends Sep 30

Latest reported revenue, Q3 FY2026$14.4mRevenue, Q3 FY2026, three months to 2026-06-30$14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 12, 2026.

Latest quarter: Q3 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$14.4mRevenue, Q3 FY2026, three months to 2026-06-30$14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure−21.6% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−120.0%Operating margin, Q3 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$17.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure−16.9 pts on a year earlier
  • Net margin−135.8%Net margin, Q3 FY2026, three months to 2026-06-30. net income / revenueNet income: −$19.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure−36.1 pts on a year earlier
  • Diluted EPS−$0.67Diluted EPS, Q3 FY2026, three months to 2026-06-30−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure+21.2% on a year earlier
  • Free cash flow−$10.0mFree cash flow, Q3 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 9-month figure less the 6-month figure.Capital expenditure: $7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 9-month figure less the 6-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$14.4mOperating margin −120.0%
Diluted EPS−$0.67, Q3 FY2026
Free cash flow−$10.0m, Q3 FY2026
Enanta Pharmaceuticals Inc, key figures for the last eight quarters
Line itemUnitQ4 FY20242024-09-30Q1 FY20252024-12-31Q2 FY20252025-03-31Q3 FY20252025-06-30Q4 FY20252025-09-30Q1 FY20262025-12-31Q2 FY20262026-03-31Q3 FY20262026-06-30Shape over the periods
Revenue$m14.6Revenue, Q4 FY2024, three months to 2024-09-30$14.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure17.0Revenue, Q1 FY2025, three months to 2024-12-31$17.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure14.9Revenue, Q2 FY2025, three months to 2025-03-31$14.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure18.3Revenue, Q3 FY2025, three months to 2025-06-30$18.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure15.1Revenue, Q4 FY2025, three months to 2025-09-30$15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure18.6Revenue, Q1 FY2026, three months to 2025-12-31$18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure17.2Revenue, Q2 FY2026, three months to 2026-03-31$17.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure14.4Revenue, Q3 FY2026, three months to 2026-06-30$14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(204.4%)Operating margin, Q4 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$29.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Revenue: $14.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure(138.8%)Operating margin, Q1 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$23.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Revenue: $17.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(164.3%)Operating margin, Q2 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$24.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Revenue: $14.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure(103.2%)Operating margin, Q3 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $18.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure(121.6%)Operating margin, Q4 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$18.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Revenue: $15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure(60.5%)Operating margin, Q1 FY2026, three months to 2025-12-31. operating income / revenueOperating income: −$11.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Revenue: $18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(69.1%)Operating margin, Q2 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Revenue: $17.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure(120.0%)Operating margin, Q3 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$17.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure
Net margin%(197.3%)Net margin, Q4 FY2024, three months to 2024-09-30. net income / revenueNet income: −$28.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Revenue: $14.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure(131.4%)Net margin, Q1 FY2025, three months to 2024-12-31. net income / revenueNet income: −$22.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $17.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(151.7%)Net margin, Q2 FY2025, three months to 2025-03-31. net income / revenueNet income: −$22.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $14.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure(99.7%)Net margin, Q3 FY2025, three months to 2025-06-30. net income / revenueNet income: −$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $18.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure(123.6%)Net margin, Q4 FY2025, three months to 2025-09-30. net income / revenueNet income: −$18.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 12-month figure less the 9-month figure.Revenue: $15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure(64.1%)Net margin, Q1 FY2026, three months to 2025-12-31. net income / revenueNet income: −$11.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $18.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(76.3%)Net margin, Q2 FY2026, three months to 2026-03-31. net income / revenueNet income: −$13.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $17.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure(135.8%)Net margin, Q3 FY2026, three months to 2026-06-30. net income / revenueNet income: −$19.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $14.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)(1.05)Diluted EPS, Q1 FY2025, three months to 2024-12-31−$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(1.06)Diluted EPS, Q2 FY2025, three months to 2025-03-31−$1.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure(0.85)Diluted EPS, Q3 FY2025, three months to 2025-06-30−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figurenot reported (Diluted EPS not reported)(0.42)Diluted EPS, Q1 FY2026, three months to 2025-12-31−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(0.45)Diluted EPS, Q2 FY2026, three months to 2026-03-31−$0.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-220572.Report this figure(0.67)Diluted EPS, Q3 FY2026, three months to 2026-06-30−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Report this figure
Free cash flow$m(19.4)Free cash flow, Q4 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$10.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Capital expenditure: $9.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure(25.5)Free cash flow, Q1 FY2025, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$16.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Capital expenditure: $8.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(16.0)Free cash flow, Q2 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$13.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-220572. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001193125-26-220572. Derived: 6-month figure less the 3-month figure.Report this figure17.4Free cash flow, Q3 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $17.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 9-month figure less the 6-month figure.Capital expenditure: $155.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 9-month figure less the 6-month figure.Report this figure(7.9)Free cash flow, Q4 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-19, accession 0001193125-25-288121. Derived: 12-month figure less the 9-month figure.Report this figure(11.8)Free cash flow, Q1 FY2026, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$11.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Capital expenditure: $143.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-11, accession 0001193125-26-046502.Report this figure(7.2)Free cash flow, Q2 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$7.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-220572. Derived: 6-month figure less the 3-month figure.Capital expenditure: $15.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001193125-26-220572. Derived: 6-month figure less the 3-month figure.Report this figure(10.0)Free cash flow, Q3 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 9-month figure less the 6-month figure.Capital expenditure: $7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-12, accession 0001193125-26-345719. Derived: 9-month figure less the 6-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$65.3mOperating margin −130.7%
Diluted EPS−$3.84, FY2025
Free cash flow−$32.2m, FY2025
Enanta Pharmaceuticals Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-09-30FY20222022-09-30FY20232023-09-30FY20242024-09-30FY20252025-09-30Shape over the periods
Revenue$m97.1Revenue, FY2021, twelve months to 2021-09-30$97.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-11-22, accession 0000950170-23-065884.Report this figure86.2Revenue, FY2022, twelve months to 2022-09-30$86.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-11-27, accession 0000950170-24-131260.Report this figure79.2Revenue, FY2023, twelve months to 2023-09-30$79.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure67.6Revenue, FY2024, twelve months to 2024-09-30$67.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure65.3Revenue, FY2025, twelve months to 2025-09-30$65.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(112.9%)Operating margin, FY2021, twelve months to 2021-09-30. operating income / revenueOperating income: −$109.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-11-22, accession 0000950170-23-065884.Revenue: $97.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-11-22, accession 0000950170-23-065884.Report this figure(143.7%)Operating margin, FY2022, twelve months to 2022-09-30. operating income / revenueOperating income: −$123.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-11-27, accession 0000950170-24-131260.Revenue: $86.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-11-27, accession 0000950170-24-131260.Report this figure(173.2%)Operating margin, FY2023, twelve months to 2023-09-30. operating income / revenueOperating income: −$137.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121.Revenue: $79.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(179.9%)Operating margin, FY2024, twelve months to 2024-09-30. operating income / revenueOperating income: −$121.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121.Revenue: $67.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(130.7%)Operating margin, FY2025, twelve months to 2025-09-30. operating income / revenueOperating income: −$85.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121.Revenue: $65.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure
Net margin%(81.4%)Net margin, FY2021, twelve months to 2021-09-30. net income / revenueNet income: −$79.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-11-22, accession 0000950170-23-065884.Revenue: $97.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-11-22, accession 0000950170-23-065884.Report this figure(141.3%)Net margin, FY2022, twelve months to 2022-09-30. net income / revenueNet income: −$121.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-11-27, accession 0000950170-24-131260.Revenue: $86.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-11-27, accession 0000950170-24-131260.Report this figure(169.0%)Net margin, FY2023, twelve months to 2023-09-30. net income / revenueNet income: −$133.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121.Revenue: $79.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(171.6%)Net margin, FY2024, twelve months to 2024-09-30. net income / revenueNet income: −$116.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-11-19, accession 0001193125-25-288121.Revenue: $67.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(125.4%)Net margin, FY2025, twelve months to 2025-09-30. net income / revenueNet income: −$81.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-12, accession 0001193125-26-345719.Revenue: $65.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure
Diluted EPS$ per share(3.92)Diluted EPS, FY2021, twelve months to 2021-09-30−$3.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-11-22, accession 0000950170-23-065884.Report this figure(5.91)Diluted EPS, FY2022, twelve months to 2022-09-30−$5.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-11-27, accession 0000950170-24-131260.Report this figure(6.38)Diluted EPS, FY2023, twelve months to 2023-09-30−$6.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(5.48)Diluted EPS, FY2024, twelve months to 2024-09-30−$5.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(3.84)Diluted EPS, FY2025, twelve months to 2025-09-30−$3.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure
Free cash flow$m(70.7)Free cash flow, FY2021, twelve months to 2021-09-30. operating cash flow − capital expenditureOperating cash flow: −$70.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-11-22, accession 0000950170-23-065884.Capital expenditure: $750.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-11-22, accession 0000950170-23-065884.Report this figure(86.9)Free cash flow, FY2022, twelve months to 2022-09-30. operating cash flow − capital expenditureOperating cash flow: −$84.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-11-27, accession 0000950170-24-131260.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-11-27, accession 0000950170-24-131260.Report this figure(112)Free cash flow, FY2023, twelve months to 2023-09-30. operating cash flow − capital expenditureOperating cash flow: −$103.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-19, accession 0001193125-25-288121.Capital expenditure: $9.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(96.7)Free cash flow, FY2024, twelve months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$78.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-19, accession 0001193125-25-288121.Capital expenditure: $17.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure(32.2)Free cash flow, FY2025, twelve months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$19.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-11-19, accession 0001193125-25-288121.Capital expenditure: $12.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-11-19, accession 0001193125-25-288121.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Enanta Pharmaceuticals Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Jupiter Topco LLC2026-06-30$53.3m3,654,920Not compared
JANUS HENDERSON GROUP PLC2026-03-31$47.7m3,784,055Not compared
BlackRock, Inc.2026-06-30$47.3m3,244,448Added+140,680
FARALLON CAPITAL MANAGEMENT, L.L.C.2026-06-30$35.3m2,418,202Reduced−453,660
Deep Track Capital, LP2026-06-30$21.1m1,444,167Reduced−512,700
ADAR1 Capital Management, LLC2026-06-30$19.6m1,344,510Added+1,293,153
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$17.7m1,211,769Added+33,720
Spruce Street Capital LP2026-06-30$15.9m1,088,731Added+156,133
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$14.7m1,011,494Added+62,590
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$11.3m776,634Added+51,573

Recent filings

All 830 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Enanta Pharmaceuticals Inc, recent filings
FiledFormWhat it isAccession number
2026-10-2916:05 ET8-K8.01 Other events0001193125-26-437774
2026-10-2807:14 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-435092
2026-08-1207:00 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-345719
2026-08-1016:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-342336
2026-07-0216:56 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001193125-26-294837
2026-06-2317:28 ET8-K8.01 Other events0001193125-26-279803
2026-06-1807:12 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-274950
2026-05-1307:00 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-220572
2026-05-1116:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-216735
2026-03-2608:00 ET8-K8.01 Other events0001193125-26-125113

Latest annual report

Form 10-K for the fiscal year ended Sep 30, 2025Filed Nov 19, 2025. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q4 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1177648
Tickers
ENTA
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Sep 30
Incorporated in
not reported
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:06 ET. Listed shows no prices and gives no investment advice.